NCT00698087View on ClinicalTrials.gov

Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 1995

Primary Completion Date

February 29, 1996

Study Completion Date

February 29, 1996

Conditions
Hepatitis B
Interventions
BIOLOGICAL

MPL-Adjuvanted recombinant hepatitis B vaccine

Intramuscular injection, 2 or 3 doses, 2 different formulations

BIOLOGICAL

Engerix™-B

Intramuscular injection, 2 or 3 doses

Trial Locations (1)

Unknown

GSK Clinical Trials Call Center, Vienna

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY